MIGUEL MOLINA REYNOSO: Open Payments
NPI 1689283384 · NAPLES, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,036 in 116 payments from 14 companies in 2025. Trend: 2023 $1,933 · 2024 $1,892 · 2025 $2,036
Food & beverage: $1,931Education: $104
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 16 | $291 |
| Alkermes, Inc. | 13 | $282 |
| Otsuka America Pharmaceutical, Inc. | 17 | $248 |
| Neurocrine BioSciences, Inc. | 11 | $212 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $164 |
| E.R. Squibb & Sons, L.L.C. | 11 | $158 |
| Lundbeck LLC | 11 | $155 |
| Janssen Pharmaceuticals, Inc | 7 | $149 |
| Indivior Inc. | 5 | $111 |
| Vanda Pharmaceuticals Inc. | 4 | $109 |
Products named: REXULTI, INGREZZA, ARISTADA, CAPLYTA, COBENFY, INVEGA SUSTENNA, ABILIFY ASIMTUFII, SUBLOCADE.
Industry payments across FL — which companies pay providers there.
